公开(公告)号：US20230139737A1

公开(公告)日：2023-05-04

申请号：US17832214

申请日：2022-06-03

申请人： FRED HUTCHINSON CANCER CENTER

发明人： Rachel PERRET ,  Philip D. GREENBERG ,  Thomas M. SCHMITT ,  Aude G. CHAPUIS ,  Ingunn M. STROMNES ,  Tijana MARTINOV

IPC分类号： A61K38/17 ,  A61P35/00 ,  A61K35/17

摘要： The present disclosure provides compositions and methods for targeting a Ras antigen to, for example, treat or prevent cancer. Disclosed embodiments include binding proteins, such as a T cell receptor or a chimeric antigen receptor, that bind to a Ras antigen:HLA complex. Polynucleotides encoding such binding protein can introduced into a host cell, such as a T cell, and the cell can be used in immunotherapy for treating various cancers. Also provided are immunogenic polypeptides that can be useful to, for example, induce an immune response against a mutated Ras or to identify a binding protein that binds to a Ras antigen.

公开(公告)号：US11639508B2

公开(公告)日：2023-05-02

申请号：US16631069

申请日：2018-07-13

申请人： The Johns Hopkins University

发明人： David A. Kass ,  Mark J. Ranek ,  Kristen Kokkonen ,  Jonathan D. Powell ,  Chirag Patel

IPC分类号： C12N15/85 ,  A61K35/17

摘要： Provided herein are engineered TSC2 polypeptides, and nucleic acid sequences encoding them, in which the ability of a serine residue to be phosphorylated is altered. In some aspects, the TSC2 serine residue cannot be phosphorylated (e.g., by substituting the serine residue with an alanine residue). In some aspects, the TSC2 serine acts as if it is constitutively phosphorylated (e.g., by substituting the serine residue with a glutamic acid residue). Also provided herein are engineered immune cells comprising altered TSC2 polypeptides or nucleic acid sequences encoding them, and methods of making and using such engineered immune cells.

公开(公告)号：US11639387B2

公开(公告)日：2023-05-02

申请号：US17037381

申请日：2020-09-29

申请人： Seattle Children's Hospital

发明人： Michael Jensen

IPC分类号： C07K16/28 ,  A61K35/17 ,  C12N5/0783 ,  A61K38/00 ,  A61K47/68 ,  C07K16/46 ,  A61K38/17 ,  C07K14/725 ,  C07K14/705 ,  C07K14/71 ,  C12N7/00 ,  A61K39/00

摘要： The invention is directed to a bispecific chimeric antigen receptor, comprising: (a) at least two antigen-specific targeting regions; (b) an extracellular spacer domain; (c) a transmembrane domain; (d) at least one co-stimulatory domain; and (e) an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain Fv (scFv) fragment, and binds a different antigen, and wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control. The invention also provides methods and uses of the bispecific chimeric antigen receptors.

公开(公告)号：US11638723B2

公开(公告)日：2023-05-02

申请号：US17173632

申请日：2021-02-11

申请人： Assistance Publique—Hopitaux de Paris ,  Fondation Imagine—Institut des Maladies Génétiques ,  Université Paris Cité ,  Institut National de la Santé et de la Recherche Médicale (INSERM)

发明人： Isabelle André ,  Marina Cavazzana ,  Kuiying Ma ,  John Tchen ,  Tayebeh-Shabi Soheili ,  Ranjita Devi Moirangthem

IPC分类号： C12N5/00 ,  C12N15/63 ,  C12N5/02 ,  A61K35/17 ,  C12N5/0783 ,  A61K31/70

摘要： The invention relates to an in vitro method to generate T cell progenitors, comprising the step of culturing CD34+ cells in a medium containing TNF-alpha and/or an antagonist of the Aryl hydrocarbon/Dioxin receptor, in particular StemRegenin 1 (SR1), in presence of a Notch ligand and optionally a fibronectin fragment.

公开(公告)号：US20230131917A1

公开(公告)日：2023-04-27

申请号：US17508446

申请日：2021-10-22

申请人： FullHope Biomedical Co., Ltd

发明人： JAN-MOU LEE ,  CHUN-WEI YU ,  CHIH-HAO FANG ,  YA-FANG CHENG

IPC分类号： C12N5/0783 ,  A61K35/17 ,  C07K14/55 ,  C07K14/54

摘要： This disclosure provides modified T cells possessing both cell killing function and antigen presenting cell function and method of culturing the same. By administration of the modified T cell, cancer cells in a subject may be effectively inhibited0 via cell-mediated immunity.

公开(公告)号：US20230128917A1

公开(公告)日：2023-04-27

申请号：US17931701

申请日：2022-09-13

申请人： CRISPR Therapeutics AG

发明人： Daniel Robert Hostetter ,  Ismael Oumzil ,  Brian Christopher Fochtman ,  John Michael Louis Toomey

IPC分类号： A61K35/17 ,  C07K14/705 ,  C07K14/725

摘要： Genetically engineered immune cells such as T cells having a disrupted CD83 gene and optionally expressing a chimeric antigen receptor (CAR) and therapeutic applications thereof. Such genetically engineered immune cells may further comprise a disrupted TRAC gene, a disrupted β2M gene, or a combination thereof.

公开(公告)号：US20230128188A1

公开(公告)日：2023-04-27

申请号：US17818106

申请日：2022-08-08

申请人： Inhibrx, Inc.

发明人： John C. Timmer ,  William Crago ,  Kyle Jones ,  Katelyn Willis ,  Florian Sulzmaier ,  Bryan Becklund ,  Brendan P. Eckelman

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K35/17 ,  C12N15/85

摘要： Provided herein are VHH-containing polypeptides that bind OX40. In some embodiments, VHH-containing polypeptides that bind and agonize OX40 are provided. Uses of the VHH-containing polypeptides are also provided.

公开(公告)号：US20230126434A1

公开(公告)日：2023-04-27

申请号：US17836165

申请日：2022-06-09

申请人： Editas Medicine, Inc.

发明人： Jennifer Leah Gori

IPC分类号： C12N15/87 ,  A61K35/28 ,  C07K14/315 ,  C12N5/0789 ,  C12N9/22 ,  A01K67/027 ,  C12N15/10 ,  A61K35/17 ,  A61K35/545

摘要： The methods and compositions described herein surprisingly increase CRISPR/Cas-mediated gene editing in stem cells by transiently treating the cells with a stem cell viability enhancer prior to and/or after contacting the cells with one or more CRISPR/Cas9 components. Further, this treatment also surprisingly results in increased engraftment of the stem cells into the target tissue of a subject. The present disclosure also provides one or more modified CRISPR/Cas9 components which, when used in combination with the stem cell viability enhancer, further increases the frequency of gene editing in stem cells, increases stem cell viability, and increases stem cell engraftment.

公开(公告)号：US20230125550A1

公开(公告)日：2023-04-27

申请号：US17936023

申请日：2022-09-28

申请人： ARCELLX, INC.

发明人： David M. HILBERT ,  Jeffrey S. SWERS

IPC分类号： A61K35/17 ,  C07K14/725 ,  C07K14/705 ,  C07K14/715 ,  A61K47/64 ,  A61P35/00 ,  C07K14/47 ,  C07K16/28 ,  C12N15/86

摘要： D domain (DD) containing polypeptides (DDpp) that specifically bind targets of interest (e.g., BCMA, CD123, CS1, HER2, AFP, and AFP p26) are provided, as are nucleic acids encoding the DDpp, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. DDpp such as DDpp fusion proteins, are also provided as are methods of making and using the DDpp. Such uses include, but are not limited to diagnostic and therapeutic applications.

公开(公告)号：US11634498B2

公开(公告)日：2023-04-25

申请号：US16097437

申请日：2017-04-28

申请人： University of Florida Research Foundation, Incorporated

发明人： Scott A. Rivkees ,  Christopher Wendler ,  Lung-Ji Chang

IPC分类号： C07K16/28 ,  C07K14/725 ,  C07K14/705 ,  C12N5/16 ,  A61K48/00 ,  C12N9/64 ,  C12N15/86 ,  A61P35/00 ,  A61K35/17

摘要： Aspects of the disclosure relate to chimeric antigen receptors (CARs) comprising an antigen binding domain (e.g., anti-TSHR), transmembrane domain (e.g., CD28), and a cytoplasmic domain (e.g., CD27, CD-137, etc.) and a safety mechanism comprising an inducible apoptosis trigger. In some aspects, the disclosure relates to use of the CARs in T cells, compositions, kits and methods for the treatment of thyroid cancers.